影响多发性骨髓瘤预后的分子生物学异常研究进展OA北大核心CSTPCD
Research advances in molecular biological abnormalities affecting the prognosis of multiple myeloma
多发性骨髓瘤(multiple myeloma,MM)是一种以单克隆浆细胞异常增生和多灶性骨骼受累为特征的浆细胞肿瘤,多发于中老年人.随着免疫靶向治疗的飞速发展,可用于MM患者的治疗药物及联合方案越来越多样化,MM目前仍不可治愈.近些年由于核型分析、荧光原位杂交技术、流式细胞术、液体活检等分子生物学检测技术的广泛应用,MM的诊断率大为提高.同时,许多与MM预后相关的基因异常先后被发现.本文旨在总结已知的分子生物学异常与MM预后的关系,为MM患者的诊断、治疗及预后提供新的信息.
Multiple myeloma is a plasma cell tumor characterized by monoclonal plasma cell dysplasia and multifocal bone in-volvement.It mainly occurs in middle-aged and elderly people.Although proteasome inhibitors,immunomodulators and hemato-poietic stem cell transplantation have improved the survival rate of patients,MM is still incurable.In recent years,due to the wide application of molecular biological detection technologies such as karyotype analysis,FISH,flow cytometry,liquid biopsy,etc.,the diagnostic rate of MM has been greatly improved.At the same time,many gene abnormalities related to the prognosis of MM have been found successively.
李妙雨;高娅娅;高广勋
解放军空军军医大学西京医院血液内科,陕西 西安 710032陕西中医药大学,陕西 咸阳 712046
临床医学
多发性骨髓瘤基因异常预后
Multiple myelomaGenetic abnormalityPrognosis
《海南医学院学报》 2024 (012)
947-951 / 5
National Natural Science Foundation of China project(81970190);Shaanxi Province Social Development and Public Relations Key Project(2019ZDLSF02-02);National Medical Center Transformation Project(2020ZKMC01)国家自然科学基金项目(81970190);陕西省社发公关重点项目(2019ZDLSF02-02);国家医学中心转化课题(2020ZKMC01)
评论